HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Lung Cancer: Clinical Trial
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Number of participants with Adverse events
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography(DSA)for lung cancer.
详细描述
By enrolling patients with lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography(DSA)for lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Karnofsky performance status >60
- •Diagnosis of lung cancer based on histology or the current accepted radiological measures.
- •Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
- •Will receive interventional therapy
- •Life expectancy: Greater than 3 months
- •Patients' routine blood test, liver function and kidney function have no obvious abnormalities
- •Ability to understand the study protocol and a willingness to sign a written informed consent document
排除标准
- •Patients with other primary tumor except lung cancer
- •History of coagulation disorders or anemia
研究组 & 干预措施
HepaSphere
lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography(DSA)
干预措施: interventional therapy (Procedure)
control
lung cancer patients received traditional therapy
干预措施: interventional therapy (Procedure)
结局指标
主要结局
Number of participants with Adverse events
时间窗: 1 year
次要结局
- Progress free disease (PFS)(1 year)
- Percentage of lesions interventional therapy that show no sign of recurrence 12 months after(1 year)
- Overall survival (OS)(3 year)
